Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL-172154 · 1 trial · 3 indications
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| SL-172154 | EXPERIMENTAL | Intravenous administration |
| Name | Type | Description |
|---|---|---|
| SL-172154 | DRUG | The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc. |
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject must have a his...
Top 20 of 60 competitors
SL-172154 is an investigational therapy being studied for ovarian cancer, including fallopian tube cancer and primary peritoneal carcinoma. It is a small molecule developed by Shattuck Labs, Inc. and has completed a Phase 1 clinical trial in these indications. It is not yet approved for any use.
SL-172154 is being developed by Shattuck Labs, Inc., a biotechnology company whose common stock trades on the Nasdaq under the ticker symbol STTK. Shattuck Labs is the sponsor of the clinical program evaluating SL-172154 in ovarian cancer and related gynecologic malignancies.
SL-172154 has completed a Phase 1 clinical trial. No later-phase trials have been initiated. The Phase 1 study enrolled 27 participants and was conducted in the United States. The drug remains investigational and is not approved by the FDA for any indication.
SL-172154 has been evaluated in one clinical trial, NCT04406623, titled "Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer." This completed Phase 1 trial enrolled 27 female participants aged 18 years and older with ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma in the United States.
Yes, the Phase 1 trial of SL-172154 was biomarker-selected, meaning enrollment was restricted to patients whose tumors expressed a specific biomarker. The study enrolled 27 participants with ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma. Biomarker selection is often used in early-phase oncology trials to target patients most likely to respond.